Full-Time
Medical Affairs
Data Analyst, Healthcare & Scientific
Posted on 6/11/2025
Guardant Health
1,001-5,000 employees
Blood-based tests for cancer detection and management
No salary listed
Expert
Palo Alto, CA, USA
- Advanced degree (Masters, PhD) in relevant field of study (outcomes research, epidemiology, statistics, advanced data science and/or analytics, mathematics or other relevant) is required
- 8+ years of relevant experience in health related outcomes research in the pharmaceutical or biotechnology or device environment
- Strong proficiency in R (preferred), Python, or SAS, including hands-on experience writing statistical programs
- Demonstrated ability to work in teams in a highly matrixed environment
- Extensive experience in real-world data analytics, observational research study design, execution and outcome research studies
- Able to adapt to novel methodological approaches to outcomes research in a rapidly advancing field of study
- Excellent written and verbal communication skills; ability to clearly articulate and synthesize evidence to both technical and non-technical audiences
- Design, develop, oversee and execute RWE studies in support of clinical utility, health outcomes and economic value across all Guardant Health oncology diagnostics products, in collaboration with the Medical Affairs field team, cross-functional partners, and external key opinion leaders (KOLs)
- Collaborate closely with cross-functional teams to align real-world data/evidence (RWD/E) strategies and data visualization, translating scientific and clinical needs into actionable insights and ensuring the delivery of high-impact analytics and outcomes
- Independently develop, validate, and execute statistical programs within standard statistical software packages such as R, Python, SAS, and advanced analytics methods, and prepare materials for presentation to internal and external specialists and generalist audiences
- Present study results and communicate complex data in a clear, compelling way to external stakeholders, including KOLs, academic collaborators, internal collaborators, and policy-makers
- Partner with internal and external KOLs in developing scientific publications, including conference abstracts, posters for scientific conferences, peer-reviewed manuscripts, and white papers
- Experience in oncology, diagnostics field, or precision medicine is a strong plus
- Experience in designing and deploying advanced analytical techniques and algorithms to derive insights from internal and external healthcare data sources
Guardant Health specializes in blood tests that provide essential information for cancer treatment and management. Their tests are designed for patients at various stages of cancer, from early detection to advanced disease management. The company develops and sells diagnostic tests that utilize blood samples to detect, monitor, and guide treatment decisions for cancer patients. Their main product, Guardant360, is FDA-approved and helps inform treatment choices for those with advanced cancer. Guardant Health is also working on tests for early-stage cancer detection and monitoring recurrence. By focusing on non-invasive diagnostics that provide rich data, the company aims to enhance patient outcomes and lessen the impact of cancer.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Palo Alto, California
Founded
2012
Simplify's Take
What believers are saying
- Guardant Health's collaboration with Pfizer could boost revenue through new cancer therapies.
- The launch of hereditary cancer testing taps into the growing genetic testing market.
- Participation in ASMM may accelerate adoption of their diagnostic technologies.
What critics are saying
- Increased competition from Caris Life Sciences may impact Guardant Health's market share.
- Rapid technological advancements could outpace Guardant Health's product integration capabilities.
- Expansion into hereditary cancer testing may face regulatory scrutiny and compliance challenges.
What makes Guardant Health unique
- Guardant Health specializes in blood-based tests for cancer treatment and management.
- Their flagship product, Guardant360, is FDA-approved for advanced cancer treatment decisions.
- The company focuses on non-invasive, data-rich diagnostics to improve patient outcomes.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Performance Bonus
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↓ -1%2 year growth
↓ -1%Competitive landscape: Caris competes with Roche's Foundation Medicine, Guardant Health, Grail, and peers like Tempus AI.
WASHINGTON, June 4, 2025 /PRNewswire/ -- A collection of public and private sector health leaders today announced a new collaboration to help ensure current health screening measures remain aligned with the rapid advancements in FDA-approved screening technologies and clinical guidelines.The Alliance for Screening Measurement Modernization (ASMM) brings together organizations from across the healthcare sector to explore a broader framework for the timely integration of evidence into currently endorsed national health screening policies."It is critically important that clinicians have what they need to keep patients healthy, including the latest diagnostics," said Lee Fleisher, M.D., M.L., ASMM chair and founder of Rubrum Advising. "The pace of technology is accelerating rapidly, but it can take more than a decade to update the quality measures that assess compliance with current health screening recommendations. This means clinicians are not incentivized to use tests that may be quicker, safer, or less invasive for patients simply because they are built on technologies that have not yet been incorporated into the latest quality measures."Over the next six months, ASMM will:Develop a replicable, transparent framework to support measure developers with timely and appropriate pathways to update currently endorsed screening quality measuresto support measure developers with timely and appropriate pathways to update currently endorsed screening quality measures Enable the evidence-based inclusion of innovative technologies that improve diagnostic speed, accuracy, and accessibilitythat improve diagnostic speed, accuracy, and accessibility Submit a consensus white paper and policy briefs to Congressional and federal agencies for considerationASMM is led by two independent but collaborative bodies: the ASMM Quality Council, whose members are guideline-setting groups and non-profit organizations, and the Industry Council, which includes organizations that are at the forefront of transforming screening technologies to support more accurate, accessible, and timely diagnoses.The Quality Council is developing the framework and will operate independently of the Industry Council, which serves as the central forum to ensure diagnostic and imaging innovators and stakeholders have a voice in the process. Together, the councils represent a range of therapeutic areas and reflect expertise in both clinical practice and quality measure development and policy.Industry Council founding members include Geneoscopy and Guardant Health and founding members of the Quality Council include ECRI, Friends of Cancer Research, Milken Institute's FasterCures, URAC, and others.SOURCE The Alliance for Screening Measurement Modernization
Guardant Health, Inc. (NASDAQ:GH) and research collaborators have unveiled results from the largest study to date on circulating tumor DNA (ctDNA) testing in stage III colon cancer, presented at the 2025 ASCO Annual Meeting.
Guardant Health introduces nearly a dozen groundbreaking Smart Liquid Biopsy applications for Guardant360 Liquid test.
Guardant Health launches Hereditary Cancer testing for risks.